Quantcast
Last updated on April 16, 2014 at 13:48 EDT

Latest Fetal hemoglobin Stories

2013-12-09 14:00:42

New research presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans uncovers several important insights into the pathophysiology of sickle cell disease and thalassemia that may soon translate into the development of better, more targeted treatments for hundreds of thousands of patients worldwide. Sickle cell disease (SCD) is an inherited, chronic disorder affecting nearly 100,000 Americans. Instead of producing healthy red blood cells,...

2013-12-09 08:27:37

Novel Genome-Editing Approach Offers a Potential Cure for Both Diseases RICHMOND, Calif., Dec. 9, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of preclinical data from its ZFP Therapeutic program for the treatment and potential cure of both sickle cell disease (SCD) and beta-thalassemia. The data demonstrate that Sangamo's approach, using its proprietary and highly specific zinc finger nuclease (ZFN) gene-editing technology, enables...

2013-10-11 12:01:09

A research team from Dana-Farber/Boston Children's Cancer and Blood Disorders Center and other institutions has discovered a new genetic target for potential therapy of sickle cell disease (SCD). The target, called an enhancer, controls a molecular switch in red blood cells called BCL11A that, in turn, regulates hemoglobin production. The researchers—led by Daniel Bauer, MD, PhD, and Stuart Orkin, MD, of Dana-Farber/Boston Children's—reported their findings today in Science. Prior...

2013-09-10 14:24:24

Treatment for sickle cell disease has largely focused on managing pain and acute complications, but current research, including several projects at Texas Children’s Hematology Center, is now aimed at developing more efficient and progressive forms of treatment that could potentially benefit patients around the world. "Traditionally, treatment for sickle cell disease has been palliative, and there have not been a lot of options to prevent long term complications," said Dr. Alex George,...

2013-09-02 00:20:31

The St. Jude Children's Research Hospital-led national BABY HUG trial linked hydroxyurea to a 21 percent reduction in annual medical costs for young children with sickle cell anemia; savings expected to grow MEMPHIS, Tenn., Sept. 2, 2013 /PRNewswire-USNewswire/ -- A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis...

2013-06-10 08:30:34

SAN DIEGO, June 10, 2013 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized, double-blind, placebo-controlled Phase 2b study of HQK-1001 in patients with sickle cell disease. The study, initiated in July 2012, enrolled a total of 77 patients in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon. HemaQuest...

2013-05-24 08:22:36

Funding for IND Application and Clinical Trial of Novel and Potentially Curative Approach RICHMOND, Calif., May 24, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted the Company a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia based on the application of its zinc finger nuclease (ZFN) gene-editing technology in hematopoietic...

2012-12-11 12:27:53

Proof-of-concept animal study selected as one of the best presentations at 54(th) American Society of Hematology Annual Meeting and Exposition BOSTON, Dec. 11, 2012 /PRNewswire-USNewswire/ -- Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have taken the first preliminary steps toward developing a form of gene therapy for sickle cell disease. In an abstract presented on Dec. 10 at the 54(th) annual meeting of the American Society of Hematology, the research...

2012-03-12 07:10:00

SAN DIEGO, March 12, 2012 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has closed a $13 million extension of their Series B financing. The Series B Extension is being funded by its existing investors: Aberdare Ventures, De Novo Ventures, Forward Ventures, Latterell Venture Partners and Lilly Ventures. Proceeds from the financing will be...

2011-12-12 16:11:38

Young infants and toddlers with sickle cell anemia who received the drug hydroxyurea were no more likely to have cellular genetic damage than those who received a placebo or inactive medicine, said researchers from Baylor College of Medicine in Houston and St. Jude Children's Research Hospital in Memphis, Tenn., yesterday at the American Society of Hematology's annual meeting in San Diego, Calif. These findings provide further evidence of the safety of hydroxyurea for children with sickle...